NEW ORLEANS — Once-weekly survodutide was linked with substantial reductions in body weight and liver fat content among individuals with obesity and metabolic dysfunction-associated steatotic liver disease.
Researchers reported new data from the SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials of survodutide (Boehringer Ingelheim/Zealand Pharma) at the American Diabetes Association Scientific Sessions.
Survodutide is a once-weekly injectable dual glucagon/GLP-1 receptor agonist being investigated for the treatment of overweight or obesity as well as metabolic dysfunction-associated steatohepatitis or

NEW ORLEANS —Use of automated insulin delivery during hospitalization may improve glycemic outcomes for adults with insulin-treated diabetes, according to data presented at the American Diabetes Association Scientific Sessions.
In the AIDING randomized controlled trial, hospitalized adults with diabetes who used the Omnipod 5 (Insulet) automated insulin delivery system along with the Dexcom G7 continuous glucose monitor had higher time in range than patients who received multiple daily insulin injections and were monitored using a CGM.
Francisco J. Pasquel, MD, MPH, section chief of

NEW ORLEANS — New data from three phase 2b studies demonstrate substantial weight loss with berobenatide, an ultralong-acting GLP-1 receptor agonist, in people with obesity or overweight, with and without type 2 diabetes.
Both weekly and monthly dosing was feasible and well tolerated, researchers reported during a symposium at the American Diabetes Association Scientific Sessions.
Berobenatide (Pfizer) is a fully biased, long-acting injectable GLP-1 that is being investigated to reduce body weight for people with overweight or obesity.
“Berobenatide has the potential to be the first approved

NEW ORLEANS — In adults with insulin-treated type 2 diabetes, an automated insulin delivery system conferred lower HbA1c and improved time in range at 13 weeks, researchers reported at the American Diabetes Association Scientific Sessions.
As Healio previously reported, the system (twiist, Sequel) received FDA clearance in 2024 for treatment of patients with type 1 diabetes aged 6 years or older. Carol J. Levy, MD, CDCES, professor in the department of medicine and department of obstetrics, gynecology and reproductive science and director of the Mount Sinai Diabetes Center and associate